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Abstract
Background: A significant proportion of myocardial infarction (MI) patients undergo complex, coordinated perturbations at
the molecular level that may eventually drive the occurrence of ventricular dysfunction and heart failure. Despite advances
in the elucidation of key processes implicated in this condition, traditional methods relying on gene expression data and the
identification of individual biomarkers in isolation pose major limitations not only for improving prediction power, but also
for model interpretability. Mechanisms underlying clinical responses after MI remain elusive and there is no biomarker with
the capacity to accurately predict ventricular dysfunction after MI. This calls for the exploration of system-level modeling of
ventricular dysfunction in post-MI patients. Within this discovery framework key perturbations and predictive patterns are
characterized by the integrated biological activity levels observed in pathways, rather than in individual genes.
Methodology/Principal Findings: Here we report an integrative approach to identifying pathways related with ventricular
dysfunction post MI with potential prognostic and therapeutic value. We found that a diversity of pathway-level
perturbations can be profiled in samples of patients with ventricular dysfunction post MI, most of which represent major
reductions of gene expression. Highly perturbed pathways included those implicated in antigen-dependent B-cell activation
and the synthesis of leucine. By analyzing patient-specific samples encoded with information derived from highly-perturbed
pathways, it is possible to visualize differential prognostic patterns and to perform computational classification of patients
with areas under the receiver operating characteristic curve above 0.75. We also demonstrate how the integration of the
outcomes generated by different pathway-based analysis models may improve ventricular dysfunction prediction
performance.
Significance: This research offers an alternative, comprehensive view of key relationships and perturbations that may
trigger the emergence or prevention of ventricular dysfunction post-MI.
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Introduction
Heart failure (HF) isa clinical conditionthat canbe defined asthe
heart’s inability to pump enough blood to meet physiological
requirements. HF is caused by cardiac disease via the interplay of
multiple molecular and environmental factors. The major cause of
HF is ventricular dysfunction after myocardial infarction (MI). Post-
MI patients undergo molecular alterations that result in structural
and functional adaptations in the heart, and which in turn may
eventually trigger the occurrence of ventricular dysfunction and HF
[1]. Despite advances in molecular and medical research, mortality
and morbidity of HF after MI remain unacceptably high [2,3]. It
has to be acknowledged that key mechanisms underlying clinical
responses after MI remain elusive. Furthermore, currently there is
no biomarker with the capacity to accurately predict ventricular
dysfunction after MI, with the exception of brain natriuretic peptide
[4].Thus,a crucialgoalistodiscoverknowledgetopredict the onset
of ventricular dysfunction after MI.
A major challenge for translational biomedical research in the
‘‘post-genome era’’ is to disentangle the complexity of multiple
levels of ‘‘omic’’ information, which can be used to improve our
understanding of the functioning (or malfunctioning) of biological
events implicated in the development of disease. Another
important requirement is to develop computational methodologies
for facilitating the interpretation of large-scale experiments and the
prediction of clinical outcomes. Although it is known that (post-
MI) ventricular dysfunction is the by-product of the large-scale,
dynamic interaction of complex molecular systems, there is a lack
of understanding of systemic mechanisms that can aid in the
prediction and treatment of this disease.
In the past two decades, large-scale gene expression analysis has
significantly contributed to the identification of possible processes
implicated in different disease domains. However, the use of
genome-wide microarrays to identify new biomarkers is still in its
infancy especially in the cardiovascular domain. Very few studies
reported the use of transcriptomic profiling to aid in the search of
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unavailability of cardiac tissue. In an interesting study published
by Wingrove et al. [6], gene expression of peripheral blood cells
was found to be correlated with the severity of coronary artery
disease, opening up new avenues for the search of cardiovascular
biomarkers. Indeed, the possibility to use transcriptomic biosigna-
tures of blood cells to predict clinical outcome after MI is
particularly attractive.
The standard approach to biomarker discovery based on gene
expression data typically involves two main steps: a) detection of
differentially expressed genes, and b) the description of the
resulting sets of genes in terms of their involvement in specific
biological processes. The former is commonly achieved with
different (univariate) statistical testing procedures. The latter can
be done by estimating the statistical ‘‘enrichment’’ of standard
functional annotations in the set of genes, such as those defined in
the Gene Ontology (GO) and the KEGG pathways databases [7].
Despite its proven utility for guiding biomarker research, this
standard approach presents different limitations related to both the
accuracy and interpretability of the resulting predictive models [8].
Previous research suggests, for example, that biomarkers
discovered under this traditional framework may: a) be difficult
to reproduce using independent datasets, b) lack predictive
robustness when evaluated with different computational prediction
model and datasets, c) be more difficult to interpret in the context
of previous and emerging evidence [9,10,11].
This may be explained in part by the possibility that highly-
differentially expressed genes encode ‘‘downstream effectors’’ or
‘‘reflectors’’ of biological malfunction, which tend to incorporate
elevated levels of both biological and experimental noise.
Furthermore, it has been suggested that an emphasis on the
detection of highly-differentially expressed genes may constrain
the identification of genes with potential causal roles in disease
[12]. This encourages the development of alternative, systems-
based methodologies that can both enhance and complement the
predictive power and interpretability of traditional approaches.
To address these concerns, bioinformatic advances for biomarker
discovery have involved the detection of differentially expressed
genes in the context of biological pathways or using network-derived
predictive features [9,10,11]. These methods allow researchers to
identify genes that may not be necessarily highly-differentially
expressed across control-case groups, but whose integration into
computational predictive models can improve prognostic accuracy.
Moreover, these methods offer a more descriptive, and possibly less
biased, approach to visualizing and explaining these predictions. For
example, the Gene Set Enrichment Analysis (GSEA) proposed by
Subramanian et al. [9] and subsequent versions of this technique
[13], enable researchers to identify lists of genes that can be used to
distinguish between control and case samples based on the
expression levels that these genes show in previously-annotated sets
of interrelated genes, i.e. canonical pathways. Several modeling
approaches to the progression and recurrence of cancer have been
recently proposed based on pathway-based signatures [10,11,12].
For instance, instead of detecting potential biomarkers as individual
genes, Chuang et al. [10] implemented a methodology in which new
breastcancerbiomarkers were represented assub-networksobtained
from protein interaction databases. Lee et al. [11] identified
condition-responsive genes, whose combined expression measure-
ments can be used to perform accurate phenotype classification.
These biomarker discovery methodologies are based on the idea of
finding statistically-detectable differences between phenotypes using
patterns of gene expression observed in specific molecular pathways.
Although one may further argue in favor of these approaches,
there is no unique or widely-accepted solution for implementing
pathway-driven biomarker discovery. In addition, these techniques
can represent alternative solutions that in combination may
enhance our understanding of mechanisms underlying the
behavior of potential biomarkers and therapeutic targets. In the
area of cardiovascular diseases, in general, and in HF research, in
particular, this type of investigations have not been sufficiently
investigated [8,14,15].
Here we report the integrated analysis of gene expression data
and molecular pathways relevant to ventricular dysfunction after
MI. We aimed to characterize this condition with regard to
perturbations observed in hundreds of pathways, and to explore
the application of this knowledge for automated prognostic tasks.
To accomplish these goals, we implemented an alternative
pathway-centric approach to identifying biomarkers and perform-
ing patient-specific classification, which differs from the techniques
introduced above in a number of ways. Such differences refer to
the way pathways are quantitatively described, ranked and applied
to perform patient-derived sample classification (Methods and
Discussion). Furthermore, we were interested in exploring the
potential descriptive and predictive complementarities that can be
brought with the proposed approach and a previously-published
method. To address this issue, we compared and integrated the
predictions made by our method with those generated by GSEA.
Methods
Research framework
In this study we searched for validated biological pathways that
show major gene expression perturbations in ventricular dysfunc-
tion.Wecompared the ‘‘levelofactivity’’ofpathways onthe basis of
gene expression measurements derived from whole-blood samples
in patients with ventricular dysfunction (VD+, ejection fraction
#40%) and in patients without ventricular dysfunction (VD2,
ejection fraction .40%) after MI. This represents an integrated
analysis framework, which comprises the combined processing of
both types of information in parallel. Figure 1 summarizes the
research pipeline implemented and main outcomes obtained.
The first analytical phase involved the selection and transfor-
mation of gene expression and molecular pathways. The gene
expression dataset, G, consisted of 32 samples originating from 16
patients with ventricular dysfunction and from 16 patients without
ventricular dysfunction post MI. A set of 639 curated molecular
pathways, MP, were analyzed. Additional information on these
datasets is provided below. Each sample, si, was encoded as a
vector of more than 15,000 gene expression values together with
their corresponding class labels. The expression measurements in
each sample, si, were mapped (overlaid) onto each pathway in
MP. This resulted in 20448 (326639) pathways reflecting the
specific gene expression levels in the different samples, i.e. each
sample was represented by the expression levels observed in 639
pathways. Of these pathways, only 637 included at least one gene
with an expression value in G. Thus, after the sample-pathway
mapping, 20384 (326637) sample-specific pathways were avail-
able for further analyses.
The activity level, hereafter referred to as L values, of each
sample-specific pathway and a global ‘‘perturbation score’’, psc, for
each pathway were estimated. A psc is computed by comparing the
L values across the VD+ and VD2 samples, as explained in the
next sub-section. The psc values provide a quantitative indication
of the alteration of gene expression in the pathways of VD+
samples in relation to VD2 samples, or vice versa. Once the psc
values were estimated, we ranked the 637 pathways to identify the
pathways exhibiting the largest gene expression perturbations in
VD+, from now on also referred to as ‘‘top pathways’’ (TP).
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characterized and can be seen as potential key mechanisms
underlying the phenotypic differences investigated here. More-
over, our hypothesis is that these pathways may also provide the
basis for prognostic applications. We compared these predictions
with those made by an alternative, published methodology (more
details below).
We explored potential prognostic applications based on the
analysis of L values that represent the samples obtained from the
VD+ and VD2 patients. Different classification models were
implemented and compared with those obtained from a well-
known gene expression analysis technique (see below). In a final
analysis phase, we assessed the integration of these methodologies
to support the discovery of potential novel biomarkers and more
powerful clinical decision-making support.
Detecting and scoring pathway perturbations in
ventricular dysfunction
Figure 2 depicts the main algorithmic steps and outcomes
required to calculate L and psc values. This is illustrated with an
example including 3 hypothetical pathways and 4 samples, which
belong to two clinical classes, A and B. For a given sample, si,aLi,k
value is calculated with respect to each pathway, MPk. The
pathways consist of sets of genes, g, which are graphically
represented with circles in Figure 2. Shaded circles are used to
indicate the intensity of the expression measurements in each
sample. Li,k is obtained by calculating the mean expression value
observed in MPk for the given sample, si. These calculations are
performed for all samples and pathways. Figure 2 portraits L
values with colored squares to reflect the magnitude of these
values. At the end of this procedure, each sample will be associated
with nL -values, and each pathway will assigned to mL -values, with
n and m representing the total number of pathways and number of
samples respectively. In our experiments n=637 and m=32. The
next step was to calculate psc values for each pathway using their
corresponding L-values. The psc value of a pathway, MPk, is equal
to the unsigned t-statistic value obtained when comparing the L
values observed across the two investigated classes, A and B. Thus,
psc estimates the magnitude of the differential change in expression
observed in MPk for the given gene expression dataset, G.
For each pathway psc value, P values were calculated to estimate
the statistical significance of these scores. This was done by
implementing a permutation-based testing procedure. The ob-
served psc values were independently compared with a null-
distribution of pscnull values. A single pscnull refers to the perturbation
scores measured in a ‘‘permuted dataset’’. A permuted dataset is
constructed by randomly permuting the class labels in the original
gene expression dataset. The null-distribution was approximated by
creating 10,000 permuted datasets and computing their corre-
sponding pscnull values. A P value reflects the proportion of pscnull
values expected to be as large (or larger) as the observed psc value.
Thus, the lower a P value, the higher the confidence that can be
assigned to the observed psc value.
Computational prognosis applications
We explored the potential application of pathway-derived
information for supporting ventricular dysfunction prognosis. We
first represented patient-specific samples using their pathway
activity levels, L, corresponding to the top 10 perturbed pathways,
TP. This information allowed us to train and test machine learning
Figure 1. Overview of research pipeline and main outcomes. Integrative pathway-based modeling of ventricular dysfunction after MI.
doi:10.1371/journal.pone.0009661.g001
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classification performances, which were obtained with an instance-
based learning classification model, KStar [16], and estimated with
leave-one-out cross-validation (LOOCV).
To further assess the relevance of the proposed approach, we
studied classification models based on genes that were detected by
GSEA as significantly differentially expressed [9]. Finally, we
assessed the predictive integration of different potential biomarkers
identified by our approach and GSEA.
Ethics Statement
The protocol was approved by the local ethics committee
(Comite ´ national d’e ´thique de la recherche ´, CNER) and written
informed consent was obtained from all patients.
Patients and gene expression data
Patients with acute MI enrolled in a national MI registry and
treated with primary percutaneous coronary intervention were
used in this study. Acute MI was defined by the presence of chest
pain ,12 hours with significant ST elevation and increase in
creatine kinase and troponin I to greater than 2-fold upper limit of
normal. Blood samples were obtained at the time of mechanical
reperfusion in PAXgene
TM tubes. Ejection fraction (EF) measured
with echocardiography using Simpson’s method 1 month after
MI was used to classify the patients into low EF (#40%; 3367%)
or high EF (.40%; 61610%) groups. Both groups of patients
were age- and sex-matched and did not differ with respect to
reperfusion time, final coronary flow, multivessel disease, history of
previous infarction, cardiovascular risk factors or treatment. As
expected, enzyme release was higher in the group of patients with
impaired EF consistent with impaired tissue perfusion. Of note, 6
patients in the VD+ group died (37%) and 3 developed heart
failure during 2 year follow-up while no patient died in the VD2
group and only 1 developed heart failure. These data confirm the
poor prognosis associated with ventricular dysfunction after MI.
Total RNA from the 32 MI patients was extracted from whole
blood cells by the PAXgene
TM technology. Transcriptomic
profiles were obtained using oligonucleotide microarrays repre-
senting 25,000 genes [17]. All data are MIAME-compliant and
available at the Gene Expression Omnibus database (www.ncbi.
nlm.nih.gov/geo/) under the accession number GSE11947.
Information resources and software tools
The collection of 639 pathways were obtained from the
Molecular Signatures Database (MSigDB) hosted at the Broad
Institute [9]. We focused on the ‘‘C2 collection’’ of canonical
pathways, which represent curated metabolic and signalling
pathways originating from different online databases. The
algorithms proposed above were implemented in our laboratory
with the Java programming language. Statistical displays were
created with the Statistica package [18]. Pathways were described
in terms of statistically detectable Gene Ontology (GO) biological
process and cellular localization terms, and were obtained with the
Fatigo tool, under the BABELOMICS (v3.1) software platform
[7]. The P values describing the statistical significance of the
overrepresentation of GO terms in the pathways were estimated
with (two-tailed) Fisher’s exact tests and corrected to account for
multiple-hypotheses testing using the Benjamini & Hochberg
Figure 2. Main algorithmic steps and outcomes in pathway perturbation detection. Identification of molecular pathways differentially
perturbed in VD+ and VD2 patients. The calculation of the psc values of 3 hypothetical pathways, MP, is illustrated here with 4 samples, s. These
samples belong to two hypothetical clinical classes or phenotypes, A and B. The psc value assigned to a pathway is computed with the t-statistic
obtained from the pathway’s activity levels, L, observed in the different samples. For a given sample, an L value is defined as the mean expression
value observed in a pathway. For example, L4,k represents the activity level of the k
th pathway, MPk, in relation to sample s4. Sample-specific
expression and L values are here shown for s1 and s4 only, dotted lines represent the samples not shown here for clarity. For a given pathway, shaded
circles are used to represent the intensity of the expression measurements in each sample. Shaded squares reflect the magnitude of L values
obtained in a given pathway in relation to a specific sample.
doi:10.1371/journal.pone.0009661.g002
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corrected P values are reported here and statistical significance is
defined at the level of P=0.05. Clustering analysis and
visualisation were implemented with the GEPAS (v4.0) platform
[19]. Supervised classification models were implemented with the
Weka software system [20].
Results
Landscape of perturbed molecular pathways in post-MI
ventricular dysfunction
The psc of 637 molecular pathways were calculated using the
gene expression data from VD+ and VD2 samples. Figure 3
provides global views of the results. In panels A, B and D, vertical
bars represent the magnitude of the psc for a given pathway. The
set of psc ranges from values near 0 to 4.70 (Figure 3A). Figure 3B
shows the corresponding P values associated with the psc. Figure 3C
presents a 3D display of the complete set of psc and P values, and
indicates that the strength of the observed perturbations is directly
proportional to their statistical significance levels. Figure 3D, a
version of Figure 3A, displays the psc across the 637 molecular
pathways together with the direction of the perturbation in
relation to VD+ patients, i.e. it reflects whether the perturbation
represents either an increase or decrease in gene expression in the
VD+ class. This was done by including the signed version of the
psc, i.e. the observed t-statistic assigned to each pathway. In this
panel, the region below the horizontal (black) line includes
pathways that exhibit a reduction of their (mean) gene expression.
Major pathway perturbations and dependencies in
post-MI ventricular dysfunction
Toassessthepotentialbiological relevance ofthepathway-specific
perturbations, we concentrated on the analysis of the pathway
showing the largest perturbations in the VD+ samples. Table 1
Figure3. Landscape ofperturbedmolecular pathwaysin post-MI ventricular dysfunction.InA, B,D verticalbars representthe magnitudeof
the perturbation score for a given pathway. A: Overview of perturbation scores, psc, (vertical axis) across 637 molecular pathways (horizontal axis). B:
Overviewof P values (verticalaxis) for the perturbation scores shown in A. C:3D displaywith the distributionof molecular pathways, perturbation scores
andP values. D: Display ofperturbation scores across637molecular pathwaystogether with the directionof the perturbationinrelation topatientswith
ventricular dysfunction: The region below the horizontal (black) line includes pathways that exhibit a reduction of their (mean) gene expression.
doi:10.1371/journal.pone.0009661.g003
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tions. The pathways are named with the standard name given in
the MSigDB. From now on, we will refer to these pathways as
top-perturbed (TP) pathways. The pathway with the strongest
perturbation is the ASBCELLPATHWAY, a pathway responsible
for antigen dependent B- cell activation. Among these pathways
found to be significantly de-regulated are: CCR3PATHWAY
(CCR3 signaling in eosinophils), HYPERTROPHY_MODEL(a
pathway implicated in time- and exercise-dependent gene regula-
tion in human skeletal muscle) [21]; and the Erk1/Erk2 Mapk
Signaling pathway (ERKPATHWAY). Table S1 offers a more
detailed functional characterizationofthese pathways, includingthe
type of gene expression change observed in relation to VD+
samples.
These pathways exhibit various functional dependencies with
regard to shared biological processes and cellular localizations.
Moreover, they functionally interrelate through proteins shared by
the different pathways. These relationships are depicted in
Figure 4. Arcs are used to indicate that any two pathways share
proteins. This illustrates the coordinated and complex functional
inter-play required to drive specific processes relevant in post-MI
ventricular dysfunction.
Pathway-specific activity levels distinguish patient clinical
outcomes
The results reported above represent system-level insights into
some of the mechanisms possibly underpinning the development
of ventricular dysfunction in post-MI patients. Motivated by the
identification of pathways displaying substantial gene expression
perturbations, we explored the application of TP activity levels to
represent patient-specific samples and to distinguish between
them. As a starting point, each sample was encoded with the
activity levels observed in each of the top 10 pathways described in
Table 1. Under this scheme, rather than using gene expression
values, each patient can be represented by 10 pathway-specific
activity levels, L values, whose calculation was described in
Methods (Figure 2).
Using this sample-encoding scheme, we implemented a
hierarchical clustering of the samples. Note that this procedure
does not incorporate information about the class (VD+ and VD2)
assigned to each sample, i.e. the clustering represents an
unsupervised classification of samples. Figure 5 presents alternative
displays of the resulting clustering based on the activity levels of the
top 10 perturbed pathways. The true class labels for each sample
are displayed. In this figure, panels A and B offer clustering
visualizations using a dendrogram and an unrooted tree
respectively. The length of the branches in these graphs reflects
the pair-wise distances between samples. These results showed that
the samples can be discriminated in terms of clinical outcome.
Same-class patients are clustered together, and dissimilar samples
are separated. The clustering visualization reveals the existence of
two major groups of patients: One grouping 14 (out of 16) VD+
samples, and the other including 14 (out of 16) VD2 samples.
These results suggest that pathway-specific activity levels may be a
useful visualization-driven, exploratory approach to clinical
decision-making support.
Table 1. Top 10 molecular pathways exhibiting the largest gene expression perturbations in VD+ samples.
TP Name psc P Genes
TP1 ASBCELLPATHWAY 4.70 1.0E-4 CD28 CD4 CD80 HLA-DRA HLA-DRB1 IL10 IL2 IL4 TNFRSF5
TNFRSF6 TNFSF5 TNFSF6
TP2 CCR3PATHWAY 4.12 2.0E-4 ARHA CCL11 CCR3 CFL1 GNAQ GNAS GNB1 GNGT1 HRAS
LIMK1 MAP2K1 MAPK3 MYL2 NOX1 PIK3C2G PLCB1
PPP1R12B PRKCA PRKCB1 PTK2 RAF1 ROCK2 MAPK1
TP3 PELP1PATHWAY 3.73 9.0E-4 CREBBP EP300 ESR1 MAPK1 MAPK3 PELP1 SRC
TP4 HYPERTROPHY_MODEL 3.60 9.0E-4 ANKRD1 ATF3 CYR61 DUSP14 EIF4E EIF4EBP1 GDF8 HBEGF
IFNG IFRD1 IL18 IL1A IL1R1 JUND MYOG NR4A3 TCF8 VEGF
WDR1
TP5 VALINE_LEUCINE_AND_ISOLEUCINE_BIOSYNTHESIS 3.55 0.0010 IARS LARS LARS2 PDHA1 PDHA2 PDHB
TP6 METPATHWAY 3.44 0.0020 ACTA1 CRK CRKL DOCK1 ELK1 FOS GAB1 GRB2 GRF2 HGF
HRAS ITGA1 ITGB1 JUN MAP2K1 MAP2K2 MAP4K1 MAPK1
MAPK3 MAPK8 MET PAK1 PIK3CA PIK3R1 PTEN PTK2 PTK2B
PTPN11 PXN RAF1 RAP1A RAP1B RASA1 SOS1 SRC STAT3
TP7 ALANINE_AND_ASPARTATE_METABOLISM 3.39 0.0026 ABAT ADSL ADSS AGXT AGXT2 ASL ASNS ASPA ASS CAD
CRAT DARS DDO GAD1 GAD2 GOT1 GOT2 GPT GPT2 NARS
PC
TP8 MPRPATHWAY 3.32 0.0025 ACTA1 ADCY1 CAP1 CCNB1 CDC2 CDC25C GNAI1 GNAS
GNB1 GNGT1 HRAS MAPK1 MAPK3 MYT1 PIN1 PRKACB
PRKACG PRKAR1A PRKAR1B PRKAR2A PRKAR2B RPS6KA1
SRC
TP9 SIG_REGULATION_OF_THE_ACTIN_CYTOSKELETON _BY_RHO_GTPASES 3.32 0.0025 ACTG1 ACTG2 ACTR2 ACTR3 AKT1 ANGPTL2 CDC42 CFL1
CFL2 FLNA FLNC FSCN1 FSCN2 FSCN3 GDI1 GDI2 LIMK1
MYH2 MYLK MYLK2 PAK1 PAK2 PAK3 PAK4 PAK6 PAK7 PFN1
PFN2 RHO ROCK1 ROCK2 RPS4X VASP WASF1 WASL
TP10 ERKPATHWAY 3.23 0.0027 DPM2 EGFR ELK1 GNAS GNB1 GNGT1 GRB2 HRAS IGF1R
ITGB1 KLK2 MAP2K1 MAP2K2 MAPK1 MAPK3 MKNK1 MKNK2
MYC NGFB NGFR PDGFRA PPP2CA PTPRR RAF1 RPS6KA1
RPS6KA5 SHC1 SOS1 SRC STAT3
psc: perturbation scores. P: Statistical significance of the perturbation. TP: Top pathway number.
doi:10.1371/journal.pone.0009661.t001
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The unsupervised discriminatory capability of L values shown
above encourages the idea of assessing the potential application of
this information for (supervised) prognosis tasks. The L values in
each sample were used as inputs to different classification models,
which were evaluated with LOOCV. The best performances for a
single-L input were observed when encoding the samples with the L
values observed in TP1 and TP5, which are the pathways involved
in antigen dependent B-cell activation and biosynthesis of valine,
leucine and isoleucine (Table 1). Using the L values from these
pathways and models based on the KStar classifier, a maximum
AUC (area under the receiver operating characteristic curve) value
of 0.80 was obtained. Combinations of multiple L values into
integrated classification models, in general, degraded classifica-
tion performance. This indicates that these pathways contribute
redundant (correlated) information for sample classification.
However, this did not hold true for one integrated biomarker
model. The combination of the L values from TP1 and TP5
improved single-input classification performance (AUC=0.84).
TP1-specific gene expression profiles
The significant perturbation observed in TP1 motivated us to
examine the expression profiles of individual genes (and combina-
tions) in this pathway and to explore their application in prediction
models. Independent classification models were built using these
individual expression profiles as inputs. Classification models using
all measured TP1 genes as individual inputs reported AUC values
below 0.70. The best classification performance was obtained with
models based on genes CD28 and CD80 together (AUC=0.72,
KStar classifier). These results underscore the prediction power of
integrated pathway markers (L values) in comparison to standard
models based on individual gene profiles, including those derived
from highly perturbed pathways.
Alternative pathway perturbation analysis and biomarker
identification
To further illustrate the potential prognostic application of
pathway L values, we implemented classification models built on
genes identified by a published methodology for gene expression
analysis, and compared the resulting prediction performances
against the results reported above. This task was carried out with
the GSEA algorithm [9]. This technique not only allows the
identification of differentially expressed genes between the sample
categories, but also it reports in which pathways such perturba-
tions occur.
Using the same set of (637) pathways analysed above and the 32
(VD+ vs. VD2) samples, GSEA found significant gene expression
perturbationsinpathwaysthatwereincluded by our approach inthe
list of top 10 perturbed pathways (Table S2). For example, GSEA
and our approach identified ERKPATHWAY, CCR3PATHWAY,
METPATHWAY and MPRPATHWAY in the top 10 list of
molecular perturbations. In addition, other pathways were high-
lighted by GSEA which were not among our top perturbed
pathways. For example,GSEAfound that the strongest perturbation
is observed in a set of 47 genes defining a CIRCADIAN_EX-
ERCISE pathway as defined in the MSigDB (Subramanian et al.,
2005). These results illustrate not only the consistency of these two
approaches, but also, and maybe more importantly, their comple-
mentarity.
The 10 most highly differentially expressed genes detected by
GSEA were: C20orf20, QSOX1, HK2, EIF2AK2, LMNB1,
TP53RK, LY9, CCDC107, PAQR8, and SLC37A4. The following
genes showed increased expression in VD+ samples relative to VD2
samples: C20orf20, QSOX1, HK2, EIF2AK2, and LMNB1. The
other highly differentially expressed genes showed reduced expres-
sion levels in VD+ samples. Different single-gene and multiple-gene
classification models were built. With regard to single-gene models,
the best classification performances were obtained with C20orf20
(AUC=0.85) and TP53RK (AUC=0.85) using a KStar classifier
and LOOCV. Integrated classification models combining sub-sets
of genes, in general, degraded classification performance. The
combination of TP53RK and LMB1 reported a maximum AUC of
0.82.
Integrated biomarker models increase prognostic
performance
The previous sections indicate that these techniques provide
alternative, yet potentially complementary, approaches to biomark-
er discovery. This motivated us to investigate possible integrated
classification strategies,which combined input featuresderived from
our pathway-based VD+ model (L values) and from the GSEA
method (highly differentially expressed genes). We found that
differentbiomarkercombinationschemescanenhance classification
performance.
Figure 6 illustrates how such integration can generate diverse,
improved classification outcomes. Only the top single and integrated
biomarker models are shown here. The diagram depicts the
Figure 4. Interactions across perturbed pathways. Dependencies
between the top 10 molecular pathways exhibiting the largest gene
expression perturbations in VD+ samples. Nodes depict the top 10
molecular pathways exhibiting the largest gene expression perturba-
tions in VD+ samples, as described in Table 1. Arcs linking the nodes are
used to indicate functional relationships between these pathways, i.e.,
proteins are shared between any two pathways. TP1, TP4, TP5 and TP7
do not share proteins with other pathways.
doi:10.1371/journal.pone.0009661.g004
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the top 10 perturbed pathways. Each sample was encoded using its corresponding (ten) pathway activity levels. A pathway activity level for a given
sample is defined as the mean expression value observed in the pathway for the sample under consideration. A: clustering visualization using a
dendrogram. B: clustering visualization using an unrooted tree. The length of the branches reflects pair-wise distances between samples.
doi:10.1371/journal.pone.0009661.g005
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differentially expressed genes (LMB1 and TP53RK) and the activity
levels of top-perturbed pathways (TP1 and TP5). In Figure 6, lines
linking two biomarkers (genes or pathways) indicate that these
biomarkers were used as inputs to an integrated classifier. Different
dotted and solid lines are used to facilitate the visualization of the
multiple combinations. Arrows indicate the classification perfor-
mance outcome, as estimated with AUC values. When the diagram
is read from the top to the bottom, the incremental improvement in
classification performance can be visualized for the different input
feature combinations. The top classification performance was
obtained when the expression values of TP53RK and the L values
extracted from TP1 (Table 1) were used as inputs to the classification
model (AUC=0.92). These findings provide additional evidence of
the potential of our modelling approach for: a) gaining deeper
mechanistic insights into processes implicated in (post-MI) ventric-
ular dysfunction, and b) exploring potentially novel biomarker
discovery strategies.
Biological insights
We finally sought to evaluate whether our pathway-driven
analysis can provide novel insights into specific molecular and
cellular mechanisms involved in ventricular dysfunction after MI.
We started by concentrating on LMNB1, one of the top 10 most
differentially expressed genes between VD+ and VD2 samples, as
detected by GSEA. LMNB1 alone provided significant prognostic
information (Figure 6). We first confirmed the microarray data
with quantitative PCR. Indeed, a significant correlation between
both techniques was demonstrated (r=0.43, P=0.01, Pearson
correlation) and we observed more LMNB1 mRNA in blood cells
from VD+ than in those from VD2 patients (n=16 in each
group): 0.3160.14 vs. 0.2160.09 (mean 6 standard deviation,
P=0.01, Mann-Whitney Rank Sum Test). We also compared
LMNB1 expression obtained by quantitative PCR between
patients with MI and patients with atypical chest pain and
without MI. LMNB1 was more expressed in MI patients (n=22)
than in non-MI patients (n=12): 2.4761.20 vs. 1.5060.77
(P=0.007, Mann-Whitney Rank Sum Test). LMNB1 is the main
constituent of nuclear lamina, which participates in the control of
gene expression [22]. Interestingly, LMNB1 has been shown to
control oxidative stress responses [23]. Therefore, the increase of
LMNB1 expression after MI is consistent with activation of
oxidative stress. The prognostic performance of LMNB1 has
recently been reported for liver cancer [24]. Our study reveals for
the first time that LMNB1 may be a potential biomarker in the
cardiovascular arena.
One of the pathways highlighted by our pathway-specific
activity level analysis was the SIG_REGULATION_OF_
THE_ACTIN_CYTOSKELETON_BY_RHO_GTPASES path-
way (TP9, Table 1). This pathway involves the regulation of the
activation state of cofilin through phosphorylation mediated either
by PI3K-RHO-CDC42-PAK-LIMK or PLC-LIMK [25]. There
are experimental reasons to believe that this pathway is involved in
the development of ventricular dysfunction, and investigations are
ongoing in our laboratory to test this hypothesis.
In conclusion, our pathway-driven analyses enabled us to find
novel biomarkers and therapeutic targets in the setting of MI and
ventricular dysfunction. Studies in larger patient populations are
required to examine the clinical usefulness of our findings.
Shareable software system
The pathway-based modelling approach presented here has been
implemented into a computing-platform independent software tool,
which is freely available on request from the authors. This
demonstration prototype, kipuMarkers (for knowledge-driven inte-
grative identification of pathway-based biomarkers), allows users to
Figure 6. Integrated prognostic systems. Combination of pathway- and gene-based biomarkers for the classification of VD+ and VD2 samples.
The diagram is read from the top to the bottom, and depicts the predictive capacity estimated when integrating representative differentially
expressed genes (LMB1 and TP53RK) and the activity levels of top-perturbed pathways (TP1 and TP5). Only the top single and integrated biomarker
models are shown here. Lines linking two biomarkers (genes or pathways) indicate their combination as inputs to an integrated classifier. Different
dotted and solid lines are used to facilitate the visualization of the multiple combinations. Arrows indicate the classification performance outcome.
AUC: area under the ROC curve. The AUC values obtained with classification models based on single biomarkers are also shown, next to each
biomarker and between parentheses.
doi:10.1371/journal.pone.0009661.g006
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gene/protein sets that can represent known molecular pathways or
other types of biologically-meaningful groups, such as co-regulated
genes or sets of miRNA targets. The tool computes psc and P values
for all the user-defined pathways. Moreover, kipuMarkers automat-
ically generates a dataset with the samples encoded with their
corresponding pathway activity levels. The resulting dataset can
afterwards be used to develop different statistical analyses and
classification models.
Discussion
In this investigation we gained new insights into the diversity
and extent of potential perturbations observed in post-MI
ventricular dysfunction samples across hundreds of molecular
pathways. An exploration of such landscape of molecular
perturbations reveals the existence of pathways highly-altered
between VD2 and VD+, which provides not only a system-level
mechanistic understanding, but also a foundation for the
automated prediction of clinical outcomes. Moreover, this type
of research may assist in the identification of feasible therapeutic
strategies beyond the single-gene targeting paradigm.
Although the identification of putative biomarkers based on
their individual expression patterns will continue to represent a
fundamental research tool, there is a need to explore methodol-
ogies not only for improving prognostic performance, but also for
augmenting our understanding of processes defining the emer-
gence and progression of HF after MI. We showed that powerful
and descriptive models of post-MI ventricular dysfunction can be
obtained through the incorporation of gene expression and
pathway context information during the search for potential
biomarkers. This differs with the traditional discovery approach in
which gene expression analysis and process descriptions, e.g. GO
analysis of differentially expressed genes only, are implemented as
separate tasks.
Previous research also suggests that pathway-based signatures
may be more reproducible and biologically-interpretable than
traditional approaches based on the analysis of the expression of
lists of genes [9,10,12]. Furthermore, an emphasis on the detection
of highly-differentially expressed genes may represent a severe
restriction on the identification of genes with potential causal roles
in disease [12]. This is because many upstream causal factors may
be driven by mutations and events with subtle responses at the
transcriptional and post-translational levels.
An important strength of this methodology is that we can
identify potential relevant biomarkers and targets, as well as their
pathway-based activity signatures, through an unbiased and
automated analytical process. We showed how different approach-
es to estimating pathway-specific activity levels can be used to
distinguish between clinical outcomes in post-MI patients. This
was illustrated with the unsupervised and supervised analysis of
pathway perturbation patterns. Also we explored the potential
predictive value of combining pathway-based activity scores and
gene expression information obtained from an alternative,
published analysis technique. We showed how such computational
integration can improve prognostic performance. So far, brain
natriuretic peptide (BNP) is considered the golden standard for
biomarkers of ventricular dysfunction. However, in our hands, the
combination of the pathway TP1 with the gene TP53RK provided
a maximal prognostic performance with an AUC of 0.92, which is
far better than BNP alone or BNP combined with other markers
[26]. Our approach was motivated by the observation that
alternative approaches to pathway analysis can provide comple-
mentary predictive power and vistas of relevant pathways.
This alternative, yet complementary, prediction capability is a
consequence of the methodological differences exhibited by the
approaches investigated here. Our approach and GSEA [9] differ
with regard to the following aspects: pathway scoring, differential
pathway detection, and sample-specific information representation
for classification. For example, we estimate pathway activity by
calculating the mean expression value observed in a sample, while
GSEA focuses on the differential expression values observed at the
gene level. Although GSEA exploits pathway-based information to
detect relevant genes, this method emphasizes a gene-centric
approach to sample representation and classification. Nevertheless,
in connection to the identification of highly de-regulated pathways,
we also found predictive agreements between these methods. This
may be interpreted not only as an indication of the potential
relevance of these pathways, but also as supporting evidence for
the predictions made by our approach.
Among our significant findings, we found that a pathway
responsible for antigen dependent B- cell activation (TP1) could
encode a powerful feature to discriminate between VD2 and
VD+ samples. Note that this pathway does not share genes with
the other highly-altered pathways detected by our approach or
with the GSEA-derived genes (Figure 4). Such a reduction in
predictive information redundancy, together with the strong class
discriminatory power of this pathway alone, serve to explain the
good prognostic potential of this pathway in conjunction with
other potential biomarkers.
The down-regulation of TP1 in patients with VD+ appears
plausible since several of its components are known to be
protective. For instance, IL10 has been shown to be cerebropro-
tective in the setting of experimental stroke [27] and soluble
receptors of TNF-a limit its cardiotoxicity. The CCR3 receptor
has been implicated in allergy but also very recently in the growth
of choroidal vessels [28] but its implication in ventricular
dysfunction remains to be studied. Perturbation of the HYPER-
TROPHY_MODEL is also plausible since the development of HF
after MI is mediated, at least partly, by a hypertrophy of the left
ventricle. Another potentially important pathway highlighted by
our analyses is the PELP1PATHWAY. PELP1 is known to serve
as an estrogen receptor alpha coactivator with prognostic value for
several types of cancer [29,30] and is linked to the GO biological
process ‘‘response to hypoxia’’.
Perturbation of the VALINE_LEUCINE_AND_ISOLEUCINE_
BIOSYNTHESIS and ALANINE_AND_ASPARTATE_META-
BOLISM pathways suggests a de-regulation of amino acid and
protein synthesis as a potential mechanism for ventricular
dysfunction Together with the observation that other pathways of
energy metabolism are perturbed in VD+ (MPRPATHWAY and
ERKPATHWAY), our data suggest that a deregulation of
metabolism occurs in some patients after MI.
Possible limitations
A more conclusive assessment of the potential biomedical
relevance of our findings is evidently constrained by the need to
perform independent experimental validations. In the future, this
can involve the evaluation of the resulting classification models on
independent datasets, and the in vivo or in vitro perturbation of the
potentially-significant pathways in case-control samples. The
former is directly concerned with the validation of the predictive
capacity of the pathway-based patterns as prognostic biomarkers,
and the latter will be required to assess the possible therapeutic
value of some of these pathways.
Another possible limitation of our investigation is the relatively
modest size of the gene expression dataset. Nevertheless, the
integrative (pathway and gene expression) analysis strategy proposed
Heart Dysfunction Mechanisms
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unavoidable, restriction in proof-of-concept translational research
applications. By not relying on a single sparse dataset characterised by
thousands of noisy and correlated features, one contributes to the
reduction of false positive and negative predictions. There is also a
need to incorporate additional evidence regarding pathways and
other relevant gene/protein sets. The analysis approaches investigat-
ed here enable the straightforward incorporation of additional
information,whichmaybeusefultoindentifybiomarkersorpotential
therapeutic targets: sets of co-regulated genes, sub-networks of
protein-protein interactions, and clusters of genes regulated by a
common miRNA or transcription factor. A more comprehensive
coverage of (curated) network-based information, together with the
availability of new computational tools, will significantly contribute to
a more accurate and personalized patient management.
Supporting Information
Table S1 Detailed functional description of the top 10 molecular
pathways exhibiting the largest gene expression perturbations in
VD+ samples. BP and CC: Examples of biological processes and
cellular localizations highly statistically detectable in a pathway as
defined in the GO. P: statistical significance of the GO term over-
representation. Up/down indicates the direction of the change in
gene expression in the pathway, i.e., ‘‘Up’’ means that the pathway
is up-regulated in VD- in comparison to VD+. NS: Non-significant
enrichment of terms. TP: Top pathway number.
Found at: doi:10.1371/journal.pone.0009661.s001 (0.04 MB
DOC)
Table S2 Top 10 perturbed pathways detected by our approach
and by GSEA.
Found at: doi:10.1371/journal.pone.0009661.s002 (0.02 MB
DOC)
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